Novotech awarded CRO Best Practice Award
Sydney-based contract research organisation (CRO) Novotech has been awarded the CRO Best Practice Award for the third time in recent years by Frost & Sullivan.
Established in 1996, Novotech has grown to become Australia’s largest independent CRO. The company provides clinical development services across all clinical trial phases and therapeutic areas, and has been actively involved in hundreds of drug development programs for US and EU registration.
Frost & Sullivan’s Sanjeev Kumar said Novotech has “proven its excellence in the Australia and Asia-Pacific market” by delivering services and information that meet or exceed the standards of customers, doctors, patients and regulatory authorities.
“The company has exhibited a unique flexibility in terms of handling small to very large projects,” Kumar stated, referring to Novotech’s technologies for electronic data capture, pharmacovigilance and safety management, and clinical trial management. He added that the company has “created a strong brand perception in the minds of its customers, which has resulted in several long-term partnerships and alliances”.
Novotech CEO Alek Safarian said the company was honoured to be recognised once again with the Frost & Sullivan award. He said the Asia-Pacific is the fastest growing region for clinical research, and demand from Novotech’s USA and EU biotech and pharma sponsors is driving the company’s continued expansion of services in the region
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
